In re TriCor Indirect Purchaser Antitrust Litigation
We obtained a $65.7 million settlement in this case involving allegations of anticompetitive conduct in the pharmaceutical industry.
Labaton Sucharow served as co-lead counsel in this lawsuit filed on behalf of a class of consumers and businesses that purchased TriCor, a cholesterol-fighting prescription drug manufactured and marketed by defendants Abbott Laboratories and French pharmaceutical companies Fournier Industrie et Sante and Laboratoires Fournier.
Plaintiffs allege that, between April 9, 2002 and May 8, 2009, defendants unlawfully monopolized the market by changing the formulation of Tricor in an attempt to keep generic competition out of the market. The case is pending before the Honorable Sue L. Robinson in the District of Delaware.
On October 28, 2009, the court granted final approval to a $65.7 million settlement that ended the litigation. For additional information about the settlement please visit www.tricorsettlement.com.